WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced an
agreement with the German National Association of Statutory Health Insurance
Funds on the reimbursement amount for ROCTAVIAN for people with severe
hemophilia A. The company noted that this is the first gene therapy for
hemophilia to receive an agreed federal price in Germany.

BioMarin and GKV-SV have agreed on an outcome-based prospective cohort model for
ROCTAVIAN. The agreement, with a minimum term of 3 years, ensures the supply and
reimbursement for eligible patients in Germany with ROCTAVIAN.

BioMarin said it continues to work with private and public payers in the U.S. to
enable access.

For More Such Health News, visit rttnews.com.



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX